Amgen Attracts Significant Investment from Large Investors Amid Strong Earnings
Amgen Inc., a global biotechnology company, has seen significant investment from various large investors. According to MarketBeat, Public Employees Retirement System of Ohio purchased 210,024 shares of Amgen's stock during the second quarter. This new stake is valued at approximately $76,054,000.
This is not an isolated instance of investment in Amgen; other large investors have also modified their holdings of the company. MASTERINVEST Kapitalanlage GmbH purchased a new position in Amgen in the 2nd quarter valued at $4,312,000. Blue Edge Capital LLC and Redwood Investment Management LLC also bought new stakes in shares of Amgen during the second quarter.
Amgen's commercial portfolio includes biologics used in oncology, supportive care, nephrology, bone health, and cardiovascular disease. The company has a market capitalization of $236.25 billion, with a price-to-earnings ratio of 27.16 and a beta of 0.41.
The medical research company reported $6.29 earnings per share for the quarter, topping the consensus estimate by $0.67. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS, with analysts forecasting that the company will post 22.92 earnings per share for the current fiscal year.